Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia

被引:19
作者
Fonseca-Aten, M
Salvatore, CM
Mejías, A
Ríos, AM
Chávez-Bueno, S
Katz, K
Gómez, AM
McCracken, GH
Hardy, RD
机构
[1] Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
[3] Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA
关键词
D O I
10.1128/AAC.49.10.4128-4136.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mycoplasma pneumoniae is a major cause of community-acquired pneumonia. We evaluated the efficacy of LBM415, a novel peptide deformylase inhibitor antimicrobial agent, for the treatment of M. pneumoniae pneumonia in a mouse model. Eight-week-old BALB/c mice were intranasally inoculated once with 10(7) CFU of M. pneumoniae. Groups of mice were treated with LBM415 (50 mg/kg of body weight) or placebo subcutaneously daily for 13 days, starting 24 h after inoculation. Groups of mice were evaluated at the baseline; at days of treatment 1, 3, 6, and 13; and at 7 days after treatment. The MIC of LBM415 against M. pneamoniae was < 0.005 mu g/ml. LBM415-treated mice had significantly lower bronchoalveolar lavage fluid M. pneumoniae concentrations than placebo-treated mice on days 6 and 13 of treatment. Compared with placebo treatment, therapy with LBM415 significantly decreased lung histopathology scores at days 3, 6, and 13 of treatment and at 7 days after treatment. Airway obstruction was significantly lower in LBM415-treated mice than in placebo-treated mice on days 1, 3, and 6 of treatment and after 7 days of therapy, while airway hyperresponsiveness was significantly lower only on day 3 of therapy. The bronchoalveolar lavage fluid concentrations of tumor necrosis factor alpha, gamma interferon (IFN-gamma), interleukin-6 (IL-6), IL-12, KC (functional IL-8), monocyte chemotactic protein 1, macrophage inflammatory protein 1 alpha, monokine induced by IFN-gamma, and IFN-inducible protein 10 were significantly reduced in LBM415-treated mice compared with the levels in placebo-treated mice. There were no differences in the bronchoalveolar lavage fluid concentrations of granulocyte-macrophage colony-stimulating factor, IL-1 beta, IL-2, IL-4, IL-5, and IL-10 between the two groups of mice. LBM415 therapy had beneficial microbiologic, histologic, respiratory, and immunologic effects on acute murine M. pneumoniae pneumonia.
引用
收藏
页码:4128 / 4136
页数:9
相关论文
共 45 条
[1]   Peptide deformylase as an antibacterial drug target:: Target validation and resistance development [J].
Apfel, CM ;
Locher, H ;
Evers, S ;
Takács, B ;
Hubschwerlen, C ;
Pirson, W ;
Page, MGP ;
Keck, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1058-1064
[2]   EFFECTS OF NEW QUINOLONES ON MYCOPLASMA-PNEUMONIAE-INFECTED HAMSTERS [J].
ARAI, S ;
GOHARA, Y ;
AKASHI, A ;
KUWANO, K ;
NISHIMOTO, M ;
YANO, T ;
OIZUMI, K ;
TAKEDA, K ;
YAMAGUCHI, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :287-292
[3]   Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome [J].
Belperio, JA ;
Keane, MP ;
Burdick, MD ;
Lynch, JP ;
Xue, YY ;
Li, KW ;
Ross, DJ ;
Strieter, RM .
JOURNAL OF IMMUNOLOGY, 2002, 169 (02) :1037-1049
[4]   DEFINITION AND APPLICATION OF A HISTOPATHOLOGICAL SCORING SCHEME FOR AN ANIMAL-MODEL OF ACUTE MYCOPLASMA-PNEUMONIAE PULMONARY INFECTION [J].
CIMOLAI, N ;
TAYLOR, GP ;
MAH, D ;
MORRISON, BJ .
MICROBIOLOGY AND IMMUNOLOGY, 1992, 36 (05) :465-478
[5]   MYCOPLASMA-PNEUMONIAE AS A COFACTOR IN SEVERE RESPIRATORY-INFECTIONS [J].
CIMOLAI, N ;
WENSLEY, D ;
SEEAR, M ;
THOMAS, ET .
CLINICAL INFECTIOUS DISEASES, 1995, 21 (05) :1182-1185
[6]   Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor [J].
Clements, JM ;
Beckett, RP ;
Brown, A ;
Catlin, G ;
Lobell, M ;
Palan, S ;
Thomas, W ;
Whittaker, M ;
Wood, S ;
Salama, S ;
Baker, PJ ;
Rodgers, HF ;
Barynin, V ;
Rice, DW ;
Hunter, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :563-570
[7]  
CLYDE WA, 1983, YALE J BIOL MED, V56, P523
[8]   Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents [J].
Credito, K ;
Lin, GR ;
Ednie, LM ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :4033-4036
[9]   Intracellular DNA replication and long-term survival of pathogenic mycoplasmas [J].
Dallo, SF ;
Baseman, JB .
MICROBIAL PATHOGENESIS, 2000, 29 (05) :301-309
[10]   Bactericidal activity of levofloxacin against Mycoplasma pneumoniae [J].
Duffy, LB ;
Crabb, DM ;
Bing, X ;
Waites, KB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) :527-528